You are here: Industry Insights > IPO

News List

IPOs Review of Chinese Biomedical Companies in 2021 May 23, 2022
In 2021, there are 89 Chinese biomedical companies (according to the classification of "Pharmaceutical and Biological" based on the industry division method of Shenyin & Wanguo Securities) completed IPOs in the Chinese mainland, Hong Kong Region of China,
Weekly Pharmaceutical News Review of PharmaSources.com (February 21st -25th) PharmaSources/Caicai
February 28, 2022
21st -25th Feb. is the statistical time for the weekly review that covers four sections, Review, R&D, Trading, Investment & Financing, and IPO, and contains 18 pieces of information.
Rec-Biotechnology Went to Hong Kong, S.A.R., China IPO, Aiming at the HPV Vaccine Market Worth Tens of Billions and Creating an Innovation Engine of Comprehensive Vaccine PharmaSources/Yefenghong
August 02, 2021
On July 16, Rec-Biotechnology submitted its prospectus to HKEX and was accepted. Rec-Biotechnology is an innovative vaccine company, and its core product, Human Papillomavirus 9-valent Vaccine, Recombinant, is in Phase III clinical trial stage.
Which Will Go Further? Innovent or Junshi? PharmaSources/Caicai
November 10, 2020
Junshi Biosciences was officially listed on the SSE STAR Market on July 15, with the stock code: 688180 and the issue price at RMB55.5/share; the opening price surged by nearly 200%, with the market value peaking at more than RMB150 billion.
Pharmaceutical News of the Week (June. 29th-July. 3rd) | PharmaSources.com - Updates on M&A, IPO and Others PharmaSources/Caicai
July 08, 2020
Let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 29-July 3, including 29 pieces.
2021 — the year UK biotechs broke investment records CPhIonline
February 10, 2022
Initial Public Offerings totalled £1,304 million, an increase of 434% from 2020, but more needs to be done to connect the UK's life sciences and finance sectors.
Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer firstwordpharma
August 23, 2021
Vividion Therapeutics withdrew its plans for an initial public offering after announcing earlier this month that it would be acquired by Bayer for up to $2 billion, Renaissance Capital reported.
Oncology biotech Tyra Biosciences files for a $100 million IPO firstwordpharma
August 23, 2021
Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital.
XinThera Closes $50M Series B Financing firstwordpharma
August 05, 2021
XinThera, a company focused on building a small molecule oncology and immunology pipeline, announced today that the company has raised $50M in Series B financing.
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 04, 2021
Immuneering today announced the closing of its upsized initial public offering of 8,625,000 shares of Class A common stock, including the full exercise by the underwriters of their overallotment option to purchase 1,125,000 shares of Class A common stock

Previous page 1 2 3 4 5 6 7 8 9 Next page